Asia-Pacific consensus on long-term and sequential therapy for osteoporosis

被引：7

作者：

Tai, Ta-Wei ^{[1
]}

Chen, Hsuan-Yu ^{[2
,3
]}

Shih, Chien-An ^{[1
]}

Huang, Chun-Feng ^{[4
,5
,6
]}

McCcloskey, Eugene ^{[7
]}

Lee, Joon-Kiong ^{[8
]}

Yeap, Swan Sim ^{[9
]}

Cheung, Ching -Lung ^{[10
]}

Charatcharoenwitthaya, Natthinee ^{[11
]}

Jaisamrarn, Unnop ^{[12
]}

Kuptniratsaikul, Vilai ^{[13
]}

Yang, Rong-Sen ^{[2
,3
]}

Lin, Sung-Yen ^{[14
,15
,16
,17
]}

Taguchi, Akira ^{[18
,19
]}

Mori, Satoshi ^{[20
]}

Li-Yu, Julie ^{[21
]}

Bin Ang, Seng ^{[22
]}

Chan, Ding-Cheng ^{[23
,24
]}

Chan, Wai Sin ^{[25
]}

Ng, Hou ^{[26
]}

Chen, Jung-Fu ^{[27
]}

Tu, Shih-Te ^{[28
]}

Chuang, Hai-Hua ^{[28
,29
,30
,31
,32
,33
]}

Chang, Yin-Fan ^{[34
]}

Chen, Fang -Ping ^{[35
,36
]}

Tsai, Keh-Sung ^{[24
]}

Ebeling, Peter R. ^{[37
]}

Marin, Fernando ^{[38
,39
]}

Rodriguez, Francisco Javier Nistal ^{[40
]}

Shi, Huipeng ^{[41
]}

Hwang, Kyu Ri ^{[42
]}

Kim, Kwang-Kyoun ^{[43
]}

Chung, Yoon-Sok ^{[44
]}

Reid, Ian R. ^{[45
]}

Chandran, Manju ^{[46
]}

Ferrari, Serge ^{[47
,48
]}

Lewiecki, E. Michael ^{[49
,50
]}

Hew, Fen Lee ^{[9
]}

Ho-Pham, Lan T. ^{[51
]}

Nguyen, Tuan Van ^{[52
,53
,54
]}

Nguyen, Van Hy ^{[55
]}

Lekamwasam, Sarath ^{[56
]}

Pandey, Dipendra ^{[57
]}

Bhadada, Sanjay ^{[58
]}

Chen, Chung-Hwan ^{[14
,15
,16
,59
,60
,61
,62
,63
,64
]}

Hwang, Jawl Shan ^{[65
]}

Wu, Chih-Hsing ^{[34
,66
,67
]}

机构：

[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Orthoped, Coll Med, Tainan, Taiwan

[2] Natl Taiwan Univ, Dept Orthoped Surg, Coll Med, Taipei, Taiwan

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] En Chu Kong Hosp, Div Family Med, New Taipei, Taiwan

[5] Natl Yang Ming Chiao Tung Univ, Sch Med, Fac Med, Taipei, Taiwan

[6] Chaoyang Univ Technol, Dept Leisure Serv Management, Taichung, Taiwan

[7] Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Sch Med & Populat Hlth, Div Clin Med,MRC Versus Arthrit Ctr Integrated Re, Sheffield, England

[8] Beacon Hosp, Dept Orthopaed, Petaling Jaya, Selangor, Malaysia

[9] Subang Jaya Med Ctr, Dept Med, Subang Jaya, Selangor, Malaysia

[10] Univ Hong Kong, Dept Pharmacol & Pharm, Ctr Genom Sci, Pokfulam, Hong Kong, Peoples R China

[11] Thammasat Univ, Div Endocrinol & Metab, Dept Med, Fac Med, Bangkok, Thailand

[12] Chulalongkorn Univ, Ctr Excellence Menopause & Aging Women Hlth, Dept Obstet & Gynecol, Bangkok, Thailand

[13] Mahidol Univ, Dept Rehabil Med, Fac Med, Siriraj Hosp, Bangkok, Thailand

[14] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthoped, Kaohsiung, Taiwan

[15] Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan

[16] Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung, Taiwan

[17] Kaohsiung Med Univ, Sch Postbaccalaureate Med, Coll Med, Kaohsiung, Taiwan

[18] Matsumoto Dent Univ, Sch Dent, Dept Oral & Maxillofacial Radiol, Nagano, Japan

[19] Matsumoto Dent Univ, Grad Sch Oral Med, Dept Hard Tissue Res, Nagano, Japan

[20] Seirei Hamamatsu Gen Hosp, Bone & Joint Surg, Shizuoka, Japan

[21] Univ Santo Tomas, Fac Med & Surg, Dept Med, Manila, Philippines

[22] KK Womens & Childrens Hosp, Menopause Unit & Family Med Serv, Singapore, Singapore

[23] Natl Taiwan Univ Hosp, Dept Geriatr & Gerontol, Taipei, Taiwan

[24] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[25] Ctr Hosp Conde Sao Januario, Dept Internal Med Orthopaed, Macau, Peoples R China

[26] Centro Hosp Conde Sao Januario, Dept Internal Med, Macau, Peoples R China

[27] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Div Endocrinol & Metab, Dept Internal Med,Coll Med, Kaohsiung, Taiwan

[28] Changhua Christian Hosp, Div Endocrinol, Dept Internal Med, Changhua, Taiwan

[29] Chang Gung Mem Hosp, Dept Family Med, Taipei, Taiwan

[30] Chang Gung Mem Hosp, Linkou Main Branches, Taoyuan, Taiwan

[31] Chang Gung Mem Hosp, Metab & Obes Inst, Taipei, Taiwan

[32] Natl Taipei Univ Technol, Dept Ind Engn & Management, Taipei, Taiwan

[33] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[34] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Family Med, Coll Med, Tainan, Taiwan

[35] Keelung Chang Gung Mem Hosp, Dept Obstet & Gynecol, Osteoporosis Prevent & Treatment Ctr, Keelung, Taiwan

[36] Chang Gung Univ, Dept Med, Coll Med, Taoyuan, Taiwan

[37] Monash Univ, Sch Clin Sci, Dept Med, Monash Hlth, Clayton, Vic, Australia

[38] Hosp Univ Quironsalud, Dept Endocrinol, Madrid, Spain

[39] Univ Europea, Sch Med Sci, Madrid, Spain

[40] Hosp Univ Rio Hortega, Dept Orthopaed Surg & Traumatol, Valladolod, Spain

[41] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Orthooed, Natl Ctr Orthoped,Sch Med, Shanghai, Peoples R China

[42] Seoul Natl Univ, Dept Obstet Gynecol, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul, South Korea

[43] Konyang Univ, Dept Orthoped Surg, Coll Med, Daejeon, South Korea

[44] Ajou Univ, Dept Endocrinol & Metab, Sch Med, Suwon, South Korea

[45] Univ Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand

[46] Singapore Gen Hosp, Dept Endocrinol, Osteoporosis & Bone Metab Unit, Singapore, Singapore

[47] Geneva Univ Hosp, Dept Med, Serv Bone Dis, Geneva, Switzerland

[48] Fac Med, Geneva, Switzerland

[49] New Mexico Clin Res, Albuquerque, NM USA

[50] Osteoporosis Ctr, Albuquerque, NM USA

来源：

OSTEOPOROSIS AND SARCOPENIA | 2024年 / 10卷 / 01期

基金：

芬兰科学院;

关键词：

Sequential therapy; Anti-osteoporosis medication; Fracture prevention; Consensus; Asia-Pacific; BISPHOSPHONATE DRUG HOLIDAYS; POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; AMERICAN ASSOCIATION; COST-EFFECTIVENESS; POSITION PAPER; FRACTURE RISK; TERIPARATIDE; ALENDRONATE; DENOSUMAB;

D O I：

10.1016/j.afos.2024.02.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: This study aimed to present the Asia -Pacific consensus on long-term and sequential therapy for osteoporosis, offering evidence -based recommendations for the effective management of this chronic condition. The primary focus is on achieving optimal fracture prevention through a comprehensive, individualized approach. Methods: A panel of experts convened to develop consensus statements by synthesizing the current literature and leveraging clinical expertise. The review encompassed long-term anti -osteoporosis medication goals, first -line treatments for individuals at very high fracture risk, and the strategic integration of anabolic and antiresorptive agents in sequential therapy approaches. Results: The panelists reached a consensus on 12 statements. Key recommendations included advocating for anabolic agents as the first -line treatment for individuals at very high fracture risk and transitioning to antiresorptive agents following the completion of anabolic therapy. Anabolic therapy remains an option for individuals experiencing new fractures or persistent high fracture risk despite antiresorptive treatment. In cases of inadequate response, the consensus recommended considering a switch to more potent medications. The consensus also addressed the management of medication -related complications, proposing alternatives instead of discontinuation of treatment. Conclusions: This consensus provides a comprehensive, cost-effective strategy for fracture prevention with an emphasis on shared decision -making and the incorporation of country -specific case management systems, such as fracture liaison services. It serves as a valuable guide for healthcare professionals in the Asia -Pacific region, contributing to the ongoing evolution of osteoporosis management.

引用

页码：3 / 10

页数：8

共 73 条

[1] Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center [J].

Bareli, Noa ;

Gat, Roni ;

Makarov, Victoria ;

Siris, Ethel ;

Fraenkel, Merav ;

Yoel, Uri .

ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)

[2] The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [J].

Black, Dennis M. ;

Reid, Ian R. ;

Boonen, Steven ;

Bucci-Rechtweg, Christina ;

Cauley, Jane A. ;

Cosman, Felicia ;

Cummings, Steven R. ;

Hue, Trisha F. ;

Lippuner, Kurt ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Martinez, Ruvie Lou Maria ;

Tan, Monique ;

Ruzycky, Mary Ellen ;

Su, Guoqin ;

Eastell, Richard .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (02) :243-254

[3] One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].

Black, DM ;

Bilezikian, JP ;

Ensrud, KE ;

Greenspan, SL ;

Palermo, L ;

Hue, T ;

Lang, TF ;

McGowan, JA ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565

[4] ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis [J].

Bone, Henry G. ;

Cosman, Felicia ;

Miller, Paul D. ;

Williams, Gregory C. ;

Hattersley, Gary ;

Hu, Ming-yi ;

Fitzpatrick, Lorraine A. ;

Mitlak, Bruce ;

Papapoulos, Socrates ;

Rizzoli, Rene ;

Dore, Robin K. ;

Bilezikian, John P. ;

Saag, Kenneth G. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (08) :2949-2957

[5] The effect of teriparatide on fracture healing after atypical femoral fracture: A systematic review and meta-analysis [J].

Byun, Seong-Eun ;

Lee, Kyung-Jae ;

Shin, Won Chul ;

Moon, Nam Hoon ;

Kim, Chul-Ho .

OSTEOPOROSIS INTERNATIONAL, 2023, 34 (08) :1323-1334

[6]

Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL-2020-0524SUPPL

[7] The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence [J].

Chandran, Manju .

ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (05) :724-738

[8]

Chang Lo-Yu, 2018, Osteoporos Sarcopenia, V4, P47, DOI 10.1016/j.afos.2018.06.001

[9] Summary of the Thai Osteoporosis Foundation (TOPF) Clinical Practice Guideline on the diagnosis and management of osteoporosis 2021 [J].

Charatcharoenwitthaya, Natthinee ;

Jaisamrarn, Unnop ;

Songpatanasilp, Thawee ;

Kuptniratsaikul, Vilai ;

Unnanuntana, Aasis ;

Sritara, Chanika ;

Nimitphong, Hataikarn ;

Wattanachanya, Lalita ;

Chotiyarnwong, Pojchong ;

Amphansap, Tanawat ;

Phruetthiphat, Ong-Art ;

Valleenukul, Thanut ;

Chaiamnuay, Sumapa ;

Petchlorlian, Aisawan ;

Srinonprasert, Varalak ;

Tejavanija, Sirakarn ;

Kitisomprayoonkul, Wasuwat ;

Dajpratham, Piyapat ;

Chaikittisilpa, Sukanya ;

Somboonporn, Woraluk .

OSTEOPOROSIS AND SARCOPENIA, 2023, 9 (02) :45-52

[10]

Cheung Ching-Lung, 2018, Osteoporos Sarcopenia, V4, P16, DOI 10.1016/j.afos.2018.03.003

← 1 2 3 4 5 6 7 8 →